StonvexLoadingβ¦
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest newsβ¦
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview Β· 3 reports / hour Β· No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro βShare this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Ξ | Vol |
|---|---|---|---|---|
| 05-14 | $16.50 | $16.94 | +2.67% | 0.4M |
| 05-15 | $16.77 | $16.80 | +0.21% | 0.6M |
| 05-18 | $16.85 | $15.74 | -6.59% | 0.4M |
| 05-19 | $15.67 | $15.66 | -0.06% | 0.2M |
| 05-20 | $16.34 | $15.78 | -3.43% | 0.3M |
Indicator values from Polygon. Educational only β single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website β Stonvex does not proxy or store filings.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
Fundamentals not available for SPTX yet.
We pull from FMP, Finnhub, and Polygon β common gaps are very recent IPOs that haven't filed their first 10-Q, pink-sheet OTC tickers, and foreign filers without US-listed depth. The Financials tab reads SEC EDGAR directly and may still have data here.
No sell-side coverage available for SPTX yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.